Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Inovio Pharmaceuticals Inc INO

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP... see more

NDAQ:INO - Post Discussion

Inovio Pharmaceuticals Inc > Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcrip
View:
Post by whytestocks on Aug 09, 2024 8:47pm

Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcrip

Just In: $INO Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcript2024-08-09 02:30:19 ET Image source: The Motley Fool. Inovio Pharmaceuticals (NASDAQ: INO) Q2 2024 Earnings Call Aug 08, 2024 , 4:30 p.m. ET Operator Continue reading For further details see: Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call ...INO - Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcript
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities